Warning letter causes delays for follow-on glatiramer acetate

Fármacos complejos no biológicos/ Novedades | Posted 17/03/2017 post-comment0 Post your comment

US-based biotechnology firm Momenta Pharmaceuticals (Momenta) announced on 17 February 2017 that Sandoz’s contracted fill/finish manufacturing partner, Pfizer, had received a US Food and Drug Administration (FDA) warning letter.

Multiple Sclerosis V14A24

Momenta stated that approval of the abbreviated new drug application (ANDA) for its generic version of multiple sclerosis (MS) drug Copaxone (glatiramer acetate) will be dependent on resolution of Pfizer facility compliance issues. Therefore, the news is expected to cause a manufacturing delay for Momenta’s three-times-weekly Glatopa 40 mg injection.

Momenta said that ‘an approval in the first quarter of 2017 is unlikely’ but that it ‘is working with its collaboration partner Sandoz to resolve this matter in order to allow for an ANDA approval as soon as possible’.

FDA approved Momenta/Sandoz’s Glatopa 20 mg/mL injection once-daily MS therapy in April 2015 [1], as the first follow-on version of Teva Pharmaceutical Industries (Teva) blockbuster MS treatment Copaxone.

The news of the delay must come as a relief to Teva, who only received approval for the three-times-weekly formulation of Copaxone in January 2013. Teva has stated that ‘Copaxone 40 mg/mL is protected by two Orange Book patents that expire in 2030’ [2].

Related articles
Follow-on versions of glatiramer acetate in Russia and Europe

Follow-on glatiramer acetate gains European approval

1. GaBI Online - Generics and Biosimilars Initiative. FDA approves first follow-on version of glatiramer acetate [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Mar 17]. Available from: www.gabionline.net/Non-Biological-Complex-Drugs/News/FDA-approves-first-follow-on-version-of-glatiramer-acetate
2. GaBI Online - Generics and Biosimilars Initiative. Teva gains FDA approval for three-times-a-week Copaxone [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Mar 17]. Available from: www.gabionline.net/Biosimilars/General/Teva-gains-FDA-approval-for-three-times-a-week-Copaxone

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2017 Pro Pharma Communications International. All Rights Reserved.

Source: Momenta

comment icon Comments (0)
Post your comment
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010